HOUSTON, Texas, May 15 -- The University of Texas MD Anderson Cancer Center posted the following news release:

* * *

Novel CAR T cell therapy developed by UT MD Anderson researchers moves into clinical studies

*

* The novel therapy targets CD94+ relapsed or refractory T/NK cell lymphomas

* UT MD Anderson received Investigational New Drug clearance from the Food and Drug Administration to begin Phase 1 clinical trial